June 8, 2016: What's New in Gyn Cancer Research

Thirty-four #gyncsm community members chatted about What's New in Gyn Cancer Research.  Our discussion focused on research presented at the Society of Gynecologic Oncology Annual Meeting (#SGOmtg) held March 19-22 in San Diego, the American Association for Cancer Research Annual Meeting (#AACR16) held April 16-20 in New Orleans, and the American Society of Clinical Oncology Annual Meeting (#ASCO16) held June 3-7 in Chicago.

You may find the transcript here and the chat analytics here. 

We began our chat by remembering our friend and supporter of #gyncsm, Jody Schoger, #bcsm co-founder. She was an amazing advocate. 

Topic Questions / Sample Response Tweets: 

T1:Do you research new treatments and studies online? Do you follow scientific meetings like #SGOmtg, #AACR16 and #ASCO16? 

• I participate in twitter to inform patients and families of key findings from meetings using #SGOMtg #ASCO16 #AACR16
• A caution in keeping up with research is how long it can take for studies to lead to any change in practice guidelines
• Plus I want to be prepared with what options I will have if I recur again
• I find @ASCOPost emails useful.

T2:GOG 252 did not support a previous study which showed IP chemo benefit (tough treatment for many). How does this change things? 

• #ASCO16 session on GOG252 Walker: Median PFS all three arms GOG252 similar
• There is still a benefit for IP chemo - demonstrated in 3 large randomized trials We need to understand who benefits most
• Yes, Dr Gourley mentioned 3 Pos studies(GOG 104,114,172), 1 neg(252)
• I feel more confident telling patients that if they want the benefits of GOG172, we have to at least try the same regimen 
• #ASCO16 session on GOG252 Mackay-“unresolved issues” 

T3:In the hot topics of immunotherapy, precision medicine, and genetics, which #SGOmtg/ #AACR16/ #ASCO16 research excited you? 

• https://t.co/DfjMW5ZPwP adv endometrial cancer : everolimus, letrozole,metformin showed clinical benefit in ph 2study 
• I'm very excited about the interest & research on hereditary cancers and how to use this to guide targeted therapy-new options! 
• Pembrolizumab:well tolerated, showed antitumor activity pts w/ PD-L1+ adv cervical squamous cell cancer.https://t.co/P5KsDdtTUA
• Precision medicine for Gyn disease is finally taking root. It not only bevucizumab anymore
• Kurian: Genes mutations in #ovca article https://t.co/O1mgn5zqoc
•  Liquid biopsies (look for circulating tumor DNA in blood) https://t.co/PUROem0e7N 4 screening and during treatment talked about 
• There was a clear theme of trying to find out who are the responders to a given Rx - understanding the pts that benefit the most

T4: What studies reported at #ASCO16 in palliative care, survivorship, and psychosocial research could help gyn cancer survivors? 

• The data on early involvement of palliative care should be able to be extrapolated to gyn cancer patients and caregivers
• QOL may predict survival in recurrent #ovca @ASCOpost -https://t.co/te0NvFAkPJ 
• Real studies on improving chemo induced. Neuropathy with PT
• Qol: older long term #ovca survivors better QOL than younger https://t.co/OGKtr3t0oi
• It was great to see presentations beyond standard chemo treatment. ASCO. It's not just about chemo

T5: As "patient-centered" research becomes more accepted, what do you see as the role of the patient in future cancer research?

• Been great to see White House precision medicine efforts. workshop this week: Engaging participants as partners in research
• Let's start with adding quality of life components to all studies.
• Being more patient-centered means looking beyond overall survival endpoints. Also need patients in design of studies to reach.
• This from #SGOmtg patient-centered research: Accepting treatment w/ Side Effects change as Goals Change https://t.co/xhY9Wg1FRn
• Patients see so much in the practical side of clinical trials that trial designers don't think about.
• I would love to see advocates on irb. And involved in trial design

Our next #gyncsm chat is on  Wednesday  July13th  at 9pmET when we will discuss Spirituality and Quality of Life with guest @MeredithGould of #hlthsp. We hope you can join us. 

Remember patients and caregivers are invited to continue our discussion on the Smart Patients platform at https://t.co/dFCf1Mcahw. 

See you next month!

Dee Sparacio

Co-founder #gyncsm Community and Chat

Resources:
@SGO_org Society of Gynecologic Oncology: #SGOmtg Abstracts and Late-breaking Abstracts https://t.co/vjzYlqOTC1

@AACR American Association for Cancer Research: #AACR16 Abstracts https://t.co/2sZ6G7QveL

@ASCO American Society of Clinical Oncology: #ASCO16 abstracts https://t.co/3vruaogIUV

"Roundup of #OvarianCancer Abstracts From #SGOmtg on Women’s Cancer" https://t.co/7z5UlcDx17 via @ascopost

@ocrfa statement on GOG 252 https://t.co/XTjyzfOpw9

key abstracts at #ASCO16 Gyn Onc at ASCO 2016: Ovarian Cancer https://t.co/t1krzp6ymx via @YouTube

Abstracts #ASCO16 Gyn Onc at ASCO 2016: Cervical Cancer https://t.co/780LCAOh72 via @YouTube

abstract review from #ASCO16 - Gyn Onc at ASCO 2016: Endometrial Cancer https://t.co/Dsh7AdyArv via @YouTube

exercise and neuropathy: https://t.co/LZwUSbWVAi

Engaging participants as partners in research - Workshop Storify https://t.co/RrRVpndnQd via @stanfordmedx

researchers going directly to metastatic breast cancer patients. https://t.co/iV2dnxfzIY?